IP Library Granted Patent US 9,724,389
Granted Patent B2
US 9,724,389 · App. 14/509,840 · Granted Aug 8, 2017

System and method for multiphasic release of growth factors

Inventors: Sean A. F. Peel (Oakville, CA); Cameron M. L. Clokie (Toronto, CA)
Assignee: INDUCE BIOLOGICS, INC.
A61K38/1875A61K9/0024A61K9/1611A61K9/1641A61K9/1682A61K9/19A61K9/5084A61K38/18A61K38/1825A61K38/1841A61K38/1858A61K38/1866A61K47/02A61K47/10A61K47/34A61K47/48861A61L27/46A61L27/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,724,389
App. No.
14/509,840
Granted
Aug 8, 2017
Kind
B2
Abstract

A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts. The sustained release profile releases at least one growth factor over a period of days to weeks, wherein the growth factor is released at a generally constant amount over such period. The system of the invention is particularly suited for applications on bioimplants. The invention also comprises methods and kits for multiphasic delivery of at least one growth factor. The invention also comprises calcium sulphate as a carrier for releasing at least one growth factor in both single and multiphasic systems for delivering at least one growth factor at a treatment site.

Claims (16)

1. A system for multiphasic release of growth factors at a treatment site, the system comprising:

a) a delivery vehicle comprising a polymer comprising poloxamer 407 and at least one first growth factor, wherein the delivery vehicle is adapted to release the at least one first growth factor in an initial release profile over a first time period; and

b) a carrier comprising a plurality of particles having at least one second growth factor on the surfaces thereof, the carrier being adapted to release the at least one second growth factor over a second time period, wherein the second time period is of a longer duration than the first time period, and wherein the carrier comprises calcium sulphate dihydrate particles.

2. The system according to claim 1 , wherein the carrier further comprises calcium phosphate particles.

3. The system according to claim 1 , wherein the delivery vehicle is in the form of a liquid or a gel.

4. The system according to claim 1 , wherein the particles of the carrier are dispersed within the delivery vehicle.

5. The system according to claim 1 , wherein the first time period comprises hours or days.

6. The system according to claim 1 , wherein the second time period comprises days or weeks.

7. The system according to claim 1 , wherein the delivery vehicle is adapted to release at least 80% of the at least one first growth factor within a period of 72 hours.

8. The system according to claim 1 , wherein the carrier releases the at least one second growth factor in a sustained release profile over the second time period.

9. The system according to claim 1 , wherein the at least one first growth factor and the at least one second growth factor are the same.

10. The system according to claim 9 , wherein the growth factor is bone morphogenetic protein 2 (BMP-2).

11. The system according to claim 10 , wherein the delivery vehicle is adapted to release at least 10% of the total amount of the growth factor during the first time period and the carrier is adapted to release at least 50% of the total amount of the growth factor during the second time period.

12. The system according to claim 1 , wherein the delivery vehicle to carrier ratio is from 0.5:1 to 4:1 (v/v).

13. The system according to claim 1 , wherein the at least one second growth factor is applied as a solution to the carrier and then lyophilized onto the carrier.

14. The system according to claim 13 , wherein the concentration of the at least one second growth factor in the solution is from 0.5 mg/ml to 2 mg/ml.

Assignments (2)
MERGER Recorded Dec 1, 2023
From: INDUCE BIOLOGICS INC.
To: RED ROCK REGENERATION INC.
Reel/Frame 065736/0721 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2014
From: CLOKIE, CAMERON M.L.; PEEL, SEAN A.F.
To: INDUCE BIOLOGICS, INC.
Reel/Frame 033915/0217 →
Continuity (4)
Continuation PCTCA2012050738 · Oct 17, 2012
Continuation In Part PCTCA2012050234 · Apr 11, 2012
Provisional Application 61474049 · Apr 11, 2011
Related Publication 20150196620A1 · Jul 16, 2015